Jonathan G. Crowston

Jonathan G. Crowston

MBBS, FRCOphth, FRANZCO, PhD -Glaucoma

Ophthalmologist

30+ years of Experience

Male📍 East Melbourne

About of Jonathan G. Crowston

Jonathan G. Crowston is an Ophthalmologist based at 32 Gisborne Street, East Melbourne, VIC 3002, Australia.


He works with people who need help with eye sight and eye health, especially conditions that affect the optic nerve and the pressure inside the eye. That can include glaucoma and ocular hypertension (OHT). In many cases, catching these early makes a real difference, because damage can build up quietly over time.


Jonathan also looks after patients with other common eye problems. Cataracts are a big one, and he can help you understand what your options are if your vision is getting blurrier. Diabetes can affect the eyes too, so he helps people manage issues like diabetic retinopathy. At times he also supports patients with longer-term retinal changes and optic nerve problems where the cause needs careful checking.


Eye conditions can be more than just symptoms. Sometimes there are signs on scans, changes in the shape of the optic nerve, or specific patterns linked to things like pigment-dispersion problems. Jonathan focuses on taking the time to explain what’s going on, what the likely next step is, and how follow-up fits in.


Over time, he has built strong experience across both medical care and procedures. For example, he has experience with surgery such as trabeculectomy, and with cataract removal. He also deals with a range of other eye conditions and complications that can show up in clinic, including things like late-onset retinal degeneration and some less common optic nerve conditions.


Jonathan’s training and study include an MBBS, FRCOphth, and FRANZCO, plus a PhD in glaucoma and ophthalmology/vision science from University College London (UCL). He also completed ophthalmology residency and training at Moorfields Eye Hospital in London.


His research background is linked to vision science and glaucoma, which helps keep his approach grounded in evidence and long-term thinking about eye health.


He may also be involved in clinical trials where they’re relevant to a patient’s situation, particularly for eye conditions where new treatments and better ways to manage risk are being studied.


If you’re looking for an ophthalmologist in East Melbourne, Jonathan offers calm, practical care for both day-to-day eye concerns and the more serious conditions that need close monitoring.

Education

  • BSc; University of London
  • MBBS; Royal Free Hospital School of Medicine, University of London
  • PhD - Ophthalmology / Vision Science; University College London (UCL)
  • Ophthalmology Residency / Training; Moorfields Eye Hospital, London
  • FRCOphth; Royal College of Ophthalmologists (UK)
  • FRANZCO; Royal Australasian College of Ophthalmologists

Services & Conditions Treated

Ganglion CystGlaucomaOcular Hypertension (OHT)TrabeculectomyPigment-Dispersion SyndromeBullaeOptic Nerve AtrophyAlzheimer's DiseaseCataractCataract RemovalDiabetic RetinopathyEndophthalmitisIridectomyLate-Onset Retinal DegenerationLeber Hereditary Optic Neuropathy (LHON)Nearsightedness

Publications

5 total
Systemic TRPV4 inhibition worsens retinal response to acute intraocular pressure elevation in older but not younger mice.

Optometry and vision science : official publication of the American Academy of Optometry • January 30, 2025

Pei Lee, Ursula Greferath, Da Zhao, Jin Huang, Anna Y Wang, Kirstan Vessey, Vicki Chrysostomou, Erica Fletcher, Jonathan Crowston, Bang Bui

Conclusions: Previous evidence showed that transient receptor potential vanilloid 4 (TRPV4) inhibition was protective of retinal ganglion cell (RGC) loss after chronic intraocular pressure (IOP) elevation in young animals. However, the role of TRPV4 in mechanosensing IOP changes in the aging eye is not well understood. Objective: This study compared the recovery of retinal function and structure after acute IOP elevation in 3- and 12-month-old mouse eyes with and without TRPV4 inhibition. Methods: We examined retinal TRPV4 expression in 2-month-old rodent eyes using immunohistochemistry and transcript analysis of isolated macroglia and RGCs. To modulate TRPV4, mice were treated daily with either vehicle or a TRPV4 antagonist (HC-067047 10 mg/kg) delivered intraperitoneally for 7 days before and 7 days after IOP elevation (50 mmHg for 30 minutes). Retinal function and structure were assessed using dark-adapted full-field electroretinography and optical coherence tomography, respectively. Results: We showed that Müller cells strongly expressed TRPV4. Seven days after IOP elevation, RGC functional recovery was significantly poorer in older mice treated with TRPV4 antagonist compared with age-matched vehicle controls (-54 ± 7% vs. -24 ± 10%, p=0.046) and their younger TRPV4 antagonist-treated counterparts (-5 ± 5%, p<0.001). Conclusions: This study showed that there was an age-related deficit in RGC functional recovery from IOP elevation with TRPV4 inhibition.

The Association of Muscle-Related Factors With Glaucoma and Related Traits in a Large United Kingdom Population.

Investigative Ophthalmology & Visual Science • June 23, 2025

Kian Madjedi, Kelsey Stuart, Grace Yin, Robert Luben, Zihan Sun, Mahantesh Biradar, Ruiqi Hu, Paul Foster, Peng Khaw, Katharina Bell, Jonathan Crowston, Anthony Khawaja

The purpose of this study was to investigate the hypothesis that muscle-related factors influence glaucoma risk, we examined the association of grip strength (GS), thigh muscle volume (TMV), and walking pace (WP) with glaucoma and its related traits. We included UK Biobank participants with data on IOP (N = 114,284), optical coherence tomography (OCT) macular inner retinal layer thickness measures (N = 44,141) and glaucoma status (N = 105,556; 2006-2010). Linear regression was used to evaluate multivariable-adjusted associations of GS, TMV, and WP with IOP and macular inner retinal OCT parameters, and logistic regression was used to evaluate associations with glaucoma status. We additionally examined gene-GS interactions with each outcome using a polygenic risk score (PRS) that combined the effects of 2673 genetic variants associated with glaucoma. After adjustment for key anthropometric, lifestyle, and medical covariables, we found each additional standard deviation (SD) increase in GS (8.6 kg in men and 6.1 kg in women) was associated with thicker macular retinal nerve fiber layer (mRNFL) by 0.08 µm (P = 0.013) and 0.07 µm (P = 0.010) in men and women, respectively; thicker macular ganglion cell-inner plexiform layer (mGCIPL) by 0.12 µm (P = 0.003) and 0.17 µm (P < 0.001); higher IOP by 0.15 millimeters of mercury (mm Hg; P < 0.001) and 0.16 mm Hg (P < 0.001) and lower odds of glaucoma (odds ratio [OR] = 0.83, P < 0.001) in men only. The association with glaucoma was replicated in the independent EPIC-Norfolk cohort. Faster WP and greater TMV were also associated with lower odds of glaucoma in men only (P = 0.004 and P = 0.017, respectively). Stronger GS-IOP associations were observed in participants with a higher level of genetic risk for glaucoma (Pinteraction < 0.001). In this cross-sectional and gene-environment interaction study, factors relating to muscle strength, mass, and function were consistently associated with higher IOP, thicker inner retinal OCT measures in both sexes, and lower odds of glaucoma in men.

Cold exposure stimulates cross-tissue metabolic rewiring to fuel glucose-dependent thermogenesis in brown adipose tissue.

Science Advances • June 11, 2025

Harry Cutler, Sigrid Jall Rogg, Senthil Thillainadesan, Kristen Cooke, Stewart W Masson, James Sligar, Jonathan Crowston, Luke Carroll, Jacqueline Stöckli, David James, Søren Madsen

To gain insight into the root causes of metabolic dysfunction, it is essential to understand how tissues communicate and coordinate their metabolic functions. Here, we sought to address this in the context of cold exposure, a well-studied metabolic perturbation. We performed proteomics across six metabolic tissues and plasma, quantifying 11,394 proteins. Beginning our investigation in brown adipose tissue (BAT), we identified a mechanism to explain enhanced glucose utilization in cold-adapted BAT. This was characterized by select remodeling of upper glycolysis and pentose cycling to increase oxygen consumption, likely by increasing uncoupling protein 1 activity through the production of reactive oxygen species. Cold-induced remodeling of the plasma proteome appeared to underpin the ability of BAT to modify its fuel preference, stimulating lipolysis in white adipose tissue and glucose production in the liver. These findings emphasize the importance of considering metabolic adaptations in the context of the whole body and suggest overlap between the mechanisms of cold adaptation and obesity.

Metabolic analysis of sarcopenic muscle identifies positive modulators of longevity and healthspan in C. elegans.

Redox Biology • March 26, 2025

Steffi Jonk, Alan Nicol, Vicki Chrysostomou, Emma Lardner, Shu-che Yu, Gustav StĂĄlhammar, Jonathan Crowston, James Tribble, Peter Swoboda, Pete Williams

Sarcopenia is the age-related degeneration of skeletal muscle, resulting in loss of skeletal muscle tone, mass, and quality. Skeletal muscle is a source of systemic metabolites and macromolecules important for neuronal health, function, and healthy neuronal aging. Age-related loss of skeletal muscle might result in decreased metabolite and macromolecule availability, resulting in reduced neuronal function or increased susceptibility to unhealthy aging and neurodegenerative diseases. We aimed to identify muscle metabolite candidates that regulate healthy aging. C57BL/6J mice were aged to young adult (4 months) and old age (25 months) and skeletal muscle was collected. Age-related muscle loss was confirmed by reduced muscle mass, muscle fiber degeneration, reduced myosin intensity, in addition to a metabolic shift and increased DNA damage in skeletal muscle. Using a low molecular weight enriched metabolomics protocol, we assessed the metabolic profile of skeletal muscle from young adult and old age mice and identified 20 metabolites that were significantly changed in aged muscle. These metabolite candidates were tested in C. elegans assays of lifespan, healthspan, muscle, and mitochondrial morphology under normal and stressed conditions. We identified four metabolite candidates (beta-alanine, 4-guanidinobutanoic acid, 4-hydroxyproline, pantothenic acid) that, when supplemented in C. elegans provided robust gero- and mitochondrial protection. These candidates also affected life-, and health- span in C. elegans models of amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD). Our findings support that aging muscle can be used to identify novel metabolite modulators of lifespan and health and may show promise for future treatments of neurodegenerative and neuromuscular disorders.

Prediction of repeatable glaucomatous visual field defects based on cluster characteristics.

The British Journal Of Ophthalmology • February 19, 2025

Jeremy C Tan, Jack Phu, Katharina Bell, Ashish Agar, Jonathan Crowston, Giovanni Montesano

Objective: This study evaluates if characteristics (eg, location, size, volume) of clusters of defects on an initial visual field (VF) test were predictive of a repeatable defect in the subsequent two tests. Methods: Retrospective cohort study of 197 eyes of 103 patients with healthy, suspect or early glaucoma. Using the initial VF pattern deviation probability grid, we defined the number of clusters (≥1 location of p<5%) and associated size (number of adjoining defect locations) and volume (sum of corresponding total deviation values) for each cluster stratified by the four probability levels (ie, p<5%; p<2%; p<1% and p<0.5%). Results: Of 4424 locations with a defect of p<5%, only 1189 (26.9%) were repeatable. The size [area under the receiver operating characteristic curve (AUC) 0.80, CI 0.76 to 0.85)] and volume (AUC 0.80, CI 0.76 to 0.85) of clusters were predictive of a repeatable defect within the cluster. The optimal thresholds for predicting a repeatable location within each cluster at 95% specificity based on initial cluster size were >6 locations at p<5%, >4 locations at p<2%, >3 locations at p<1% and >2 locations at p<0.5%. Defining cluster defects by involvement of central or peripheral rim locations improved the predictive value compared with the entire 24-2 grid. Conclusions: The location, size and volume of clusters of defects on an initial VF test may be predictive of subsequent repeatability. This may help distinguish eyes with a higher risk of repeatable defects.

Clinical Trials

1 total

An Open-label Phase I Study to Evaluate the Safety, Tolerability and Biodegradation Period of PolyActiva PA5108 Ocular Implant When Administered Intracamerally to the Anterior Chamber of the Eye

CompletedPhase 1

A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).

Participants: 8

Frequently Asked Questions

What services does Dr Jonathan G. Crowston provide?
Dr Crowston offers a range of eye care services including glaucoma management, ocular hypertension assessment, cataract treatment and cataract removal, diabetic retinopathy care, trabeculectomy, pigment-dispersion syndrome management, and care for optic nerve issues and retinal conditions.
What conditions does he treat?
He treats glaucoma, ocular hypertension, cataracts, diabetic retinopathy, pigment disorders of the eye, late-onset retinal degeneration, Leber hereditary optic neuropathy, and related eye conditions.
Where is the clinic located?
The clinic is at 32 Gisborne Street, East Melbourne, VIC 3002, Australia.
How do I book an appointment?
To book an appointment, contact the clinic directly or inquire at the reception when you visit. You can ask about available appointment times and any pre-visit instructions.
What is Dr Crowston's experience level?
He has over 30 years of experience as an ophthalmologist and holds MBBS, FRCOphth, FRANZCO, and a PhD in Ophthalmology / Vision Science.
What should I expect at a glaucoma visit?
During a glaucoma visit, the ophthalmologist will check eye pressure, examine the optic nerve, assess visual field, and discuss treatment options such as monitoring, eye drops, or surgical procedures like trabeculectomy if needed.

Contact Information

32 Gisborne Street, East Melbourne, VIC 3002, Australia

Is this your profile?

Claim this profile →

Memberships

  • FRCOphth – Fellow of the Royal College of Ophthalmologists (UK)
  • FRANZCO – Fellow of the Royal Australasian College of Ophthalmologists